Davies G, Thomas P, Broder I, Mintz S, Silverman F, Leznoff A, Trotman C
Ann Intern Med. 1977 May;86(5):549-53. doi: 10.7326/0003-4819-86-5-549.
The efficacy of inhaled beclomethasone dipropionate has been examined in 44 steroid-dependent asthmatics observed for 9 months to 2 years. A 3-month double-blind trial found that subjects treated with beclomethasone had a significant diminution in symptoms, were able to reduce their use of medication, and had improved maximum expiratory flow rates. Approximately one half were able to discontinue the use of oral prednisone within 9 months after starting beclomethasone, and a further one third reduced their dose by at least 50%. No characteristics could be defined to predict responsiveness to beclomethasone. The effectiveness of beclomethasone was sustained for as long as 2 years and was not associated with any abnormal urine, blood, or serum values or chest X-ray findings. Candidiasis of the palate appeared in approximately one third of the subjects and was usually transient. The chronic use of beclomethasone did not result in endocrine suppression.
已对44名依赖类固醇的哮喘患者进行了9个月至2年的观察，以研究吸入用二丙酸倍氯米松的疗效。一项为期3个月的双盲试验发现，接受倍氯米松治疗的受试者症状明显减轻，能够减少药物使用量，最大呼气流量率也有所改善。大约一半的患者在开始使用倍氯米松后的9个月内能够停用口服泼尼松，另有三分之一的患者将剂量至少减少了50%。无法确定任何特征来预测对倍氯米松的反应性。倍氯米松的有效性持续了长达2年，且与任何尿液、血液或血清值异常或胸部X光检查结果无关。大约三分之一的受试者出现了腭部念珠菌病，通常为一过性。长期使用倍氯米松并未导致内分泌抑制。
